Adverum Biotechnologies (ADVM)
(Delayed Data from NSDQ)
$7.73 USD
+0.08 (1.05%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $7.73 0.00 (0.00%) 5:16 PM ET
2-Buy of 5 2
D Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.73 USD
+0.08 (1.05%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $7.73 0.00 (0.00%) 5:16 PM ET
2-Buy of 5 2
D Value C Growth C Momentum D VGM
Zacks News
Adverum Biotechnologies Enters Oversold Territory
by Zacks Equity Research
Adverum Biotechnologies has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Adverum Biotechnologies (ADVM) Upgraded to Buy: Here's Why
by Zacks Equity Research
Adverum Biotechnologies (ADVM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The Keys to Successfully Timing the Markets - September 24, 2019
by Zacks Equity Research
Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?
Adverum Reports Data From Phase I Wet AMD Study, Stock Down
by Zacks Equity Research
Adverum Biotechnologies (ADVM) announces data from one cohort of an early-stage study, evaluating its gene therapy candidate, ADVM-022, in patients with wet AMD.
The Keys to Successfully Timing the Markets - September 04, 2019
by Zacks Equity Research
Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?
Is the Options Market Predicting a Spike in Adverum Biotechnologies (ADVM) Stock?
by Zacks Equity Research
Investors need to pay close attention to Adverum Biotechnologies (ADVM) stock based on the movements in the options market lately.
What's in Store for Aytu BioScience's (AYTU) Q4 Earnings?
by Zacks Equity Research
On Aytu BioScience's (AYTU) upcoming earnings call, investor focus will be on its diversified portfolio of medicines approved to treat ailments like low testosterone, insomnia and male infertility.
The Keys to Successful Timing the Markets - August 15, 2019
by Zacks Equity Research
Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?
Adverum Biotechnologies (ADVM) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of 25.81% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo (PRGO) is focused on Consumer Self Care Americas segment. It remains to be seen if this benefits the company's results in the soon-to-be reported quarter.
Tenet Healthcare (THC) Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Tenet Healthcare's (THC) second-quarter earnings are likely to suffer due to lower revenues.
Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Adverum Biotechnologies (ADVM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Adverum (ADVM) Stock?
by Zacks Equity Research
Investors need to pay close attention to Adverum (ADVM) stock based on the movements in the options market lately.
What Makes Adverum Biotechnologies (ADVM) a New Strong Buy Stock
by Zacks Equity Research
Adverum Biotechnologies (ADVM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Adverum (ADVM) Jumps: Stock Rises 5.1%
by Zacks Equity Research
Adverum (ADVM) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Adverum Biotechnologies, Inc. (ADVM) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Adverum Biotechnologies, Inc. (ADVM).
Biotech Stock Roundup: Label Expansion for CELG's Drugs, Setback for IMGN
by Zacks Equity Research
Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
Adverum Up as FDA Lifts Hold on Cohort of Wet AMD Study
by Zacks Equity Research
Adverum's (ADVM) stock gains as the FDA lifts the clinical hold on the second cohort of an initial stage study on lead candidate.
All You Need to Know About Adverum Biotechnologies (ADVM) Rating Upgrade to Buy
by Zacks Equity Research
Adverum Biotechnologies (ADVM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on pipeline progress and updates, when Tilray (TLRY) reports first-quarter 2019 results.
Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on pipeline progress and updates, when Tilray (TLRY) reports first-quarter 2019 results.
Adverum Biotechnologies (ADVM) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of 17.86% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Evoke Pharma (EVOK) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
During Evoke Pharma's (EVOK) Q1 conference call, investor focus will be on its progress and issues related to the NDA submission for Gimoti to treat diabetic gastroparesis.
Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Adverum Biotechnologies (ADVM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Beat in the Offing for Humana's (HUM) Q1 Earnings?
by Zacks Equity Research
Humana's (HUM) Q1 earnings are likely to gain on higher membership and a solid Medicare Advantage.